FDA Warning Letter September 9, 2025 On September 9, 2025, the FDA issued a warning letter citing LumiMeds marketing claims for compounded GLP-1s as misleading, the same date a broader batch of approximately 55 warning letters was issued to telehealth platforms across the GLP-1 space, including Hims & Hers
Acid reflux and gas Other GI side effects may include gas (burping, flatulence), indigestion, and acid reflux, though these are less common than side effects like nausea and vomiting
We typically recommend a 24 week break after 812 weeks on for chronic protocols the necessity isn't fully established, but it's a sensible conservative approach for long-term use
[PMID: 39976950] PubMed record related to this compound for laboratory literature review
As of January 2026, a new oral GLP-1 has become available